Maze Therapeutics
secret to health
Maze Corporate Presentation October 2022
view our pipeline pipeline

latest press releases

December 16, 2022
Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
November 4, 2022
Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease
October 12, 2022
Maze Therapeutics Appoints Harold Bernstein, M.D., Ph.D., as President, Research and Development and Chief Medical Officer

latest media coverage

December 16, 2022
Updated: Maze reveals positive first look at PhI Pompe disease candidate
June 29, 2022
LifeSci 2nd Annual Genetic Medicines Symposium 2022
March 23, 2021
Exclusive: Maze unveils their $191M pipeline, taking on Vertex and two long-sought conditions
December 7, 2020
Maze Allies With BridgeBio and Alloy to Create 2 Biotechs
December 7, 2020
Endpoints News: Maze Therapeutics Spins Out Two New Companies with Alloy and BridgeBio
January 6, 2020
Top Life Sciences Startups to Watch in 2020
February 28, 2019
Forbes: Third Rock And ARCH-Backed Genetics Startup Launches With Nearly $200 Million
February 28, 2019
Xconomy: With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases
February 28, 2019
MIT Technology Review: The secret to a new drug could be hiding in your genes

      want to get a hold of a representative?

      Jillian Connell
      Maze Therapeutics
      jconnell@mazetx.com

      media inquires

      Katie Engleman
      1AB
      katie@1abmedia.com

      Contact Us